Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study

被引：0

作者：

Eyre, Toby ^{[1
]}

Pagel, John M. ^{[2
]}

Coombs, Catherine C. ^{[3
]}

Shah, Nirav N. ^{[4
]}

Lamanna, Nicole ^{[5
]}

Lech-Maranda, Ewa ^{[6
]}

Woyach, Jennifer ^{[7
]}

Wierda, William G. ^{[8
]}

Cheah, Chan Y. ^{[9
,10
]}

Roeker, Lindsey ^{[11
]}

Patel, Manish R. ^{[12
]}

Fakhri, Bita ^{[13
]}

Barve, Minal A. ^{[14
]}

Tam, Constantine S. ^{[15
,16
]}

Lewis, David ^{[17
]}

Gerson, James N. ^{[18
]}

Alencar, Alvaro ^{[19
]}

Taylor, Justin ^{[19
]}

Abedel-Wahab, Omar ^{[11
]}

Ghia, Paolo ^{[20
,21
]}

Schuster, Stephen J. ^{[18
]}

Chen, Jessica ^{[22
]}

Nair, Binoj ^{[23
]}

Tsai, Donald E. ^{[23
]}

Ku, Nora C. ^{[23
]}

Davids, Matthew S. ^{[24
,25
]}

Brown, Jennifer R. ^{[24
,25
]}

Jurczak, Wojciech ^{[26
]}

Mato, Anthony R. ^{[11
]}

机构：

[1] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[2] Swedish Canc Inst, Seattle, WA USA

[3] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[4] Med Coll Wisconsin, Brookfield, WI USA

[5] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[6] Inst Hematol & Transfus Med, Krakow, Poland

[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Linear Clin Res, Perth, WA, Australia

[10] Sir Charles Gairdner Hosp, Perth, WA, Australia

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[13] Univ Calif San Francisco, San Francisco, CA 94143 USA

[14] Mary Crowley Canc Res, Dallas, TX USA

[15] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[16] Univ Melbourne, Melbourne, Vic, Australia

[17] Derriford Hosp, Plymouth Hosp NHS Trust, Plymouth, Devon, England

[18] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[19] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[20] Univ Vita Salute San Raffaele, Milan, Italy

[21] IRCCS Osped San Raffaele, Milan, Italy

[22] Eli Lilly & Co, Indianapolis, IN 46285 USA

[23] Loxo Oncol Lilly, Stamford, CT USA

[24] Dana Farber Canc Inst, Boston, MA 02115 USA

[25] Harvard Med Sch, Boston, MA 02115 USA

[26] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2021-OR

引用

页码：37 / 38

页数：2

共 50 条

[1] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
Eyre, Toby
Shah, Nirav N.
Alencar, Alvaro
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal A.
Ghia, Paolo
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 142 - 143
[2] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
Cohen, Jonathon B.
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fahkri, Bita
Jurczak, Wojciech
Tan, Xuan N.
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian
Lewis, David J.
Le Gouill, Stephen
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S378 - S379
[3] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Roeker, Lindsey
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David J.
Gerson, James N.
Alencar, Alvaro
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S315 - S316
[4] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Mato, Anthony R.
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Yoon
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal
Tam, Constantine S.
Lewis, David John
Gerson, James N.
Alencar, Alvaro J.
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
BLOOD, 2020, 136
[5] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 10 - 11
[6] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
[7] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
BLOOD, 2020, 136
[8] Pirtobrutinib, A Next Generation, Highly Selective, Non-covalent BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Johnathon B.
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 171
[9] Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, Davi John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Zinzani, Pier Luigi Luigi
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Lech-Maranda, Ewa
Tam, Constantine S.
Sundaram, Suchitra
Yin, Ming
Nair, Binoj
Balbas, Minna
Tsai, Donald
Mato, Anthony R.
Cheah, Chan Yoon
BLOOD, 2021, 138
[10] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 13 - 14

← 1 2 3 4 5 →